Extended indication Extension of indication for the prevention of phototoxicity in adolescent patients (12 to under 18 years of age) with erythropoietic protoporphyria (EPP).
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Afamelanotide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension IND
Main indication Metabolic diseases
Extended indication Extension of indication for the prevention of phototoxicity in adolescent patients (12 to under 18 years of age) with erythropoietic protoporphyria (EPP).
Proprietary name Scenesse
Manufacturer Clinuvel
Mechanism of action Unknown
Route of administration Subcutaneous
Therapeutical formulation Implant
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date February 2023
Expected Registration December 2023
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost 13,986.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References medicijnkosten.nl
Additional remarks Gemiddelde prijs per 1 injectieflacon Scenesse, implantaat 16 mg € 15.370,04 incl. btw.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information